Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38,355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial.
Shi Y, Zhou K, Zhou H, Qin Y, Jing H, Xiang Y, Wang Z, Wang Z, Zang A, Bai O, Li Z, Zhang H, Song Y, Liang J, Wei M. Shi Y, et al. Among authors: song y. EClinicalMedicine. 2024 Jun 20;73:102702. doi: 10.1016/j.eclinm.2024.102702. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 39007066 Free PMC article.
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
Xu W, Zhou K, Wang T, Yang S, Liu L, Hu Y, Zhang W, Ding K, Zhou J, Gao S, Xu B, Zhu Z, Liu T, Zhang H, Hu J, Ji C, Wang S, Xia Z, Wang X, Li Y, Song Y, Ma S, Tang X, Zhang B, Li J. Xu W, et al. Among authors: song y. Am J Hematol. 2023 Apr;98(4):571-579. doi: 10.1002/ajh.26826. Epub 2023 Jan 22. Am J Hematol. 2023. PMID: 36683422 Free article. Clinical Trial.
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study.
Zhong H, Cheng S, Zhang X, Xu B, Chen J, Jiang X, Xiong J, Hu Y, Cui G, Wei J, Qian W, Huang X, Hou M, Yan F, Wang X, Song Y, Hu J, Liu Y, Ma X, Li F, Wu C, Chen J, Yu L, Bai O, Xu J, Zhu Z, Liu L, Zhou X, Huang L, Tong Y, Niu T, Wu D, Zhang H, Wang C, Ouyang B, Yi H, Song Q, Cai G, Li B, Liu J, Li Z, Xiao R, Wang L, Jiang Y, Liu Y, Zheng X, Xu P, Huang H, Wang L, Chen S, Zhao W. Zhong H, et al. Among authors: song y, song q. Innovation (Camb). 2023 Apr 13;4(3):100426. doi: 10.1016/j.xinn.2023.100426. eCollection 2023 May 15. Innovation (Camb). 2023. PMID: 37181228 Free PMC article.
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X, Qiu L, Yang J, Yang Y, Wang Z, Hu J, Wang H, Su H, Jin Z, Qian W, Jin C, Zhang M, Yu D, Liu L, Chen G, Li Y, Sun T, Jin J, Bao H, Du X, Zhou H, Fu G, Shi Y. Qin Y, et al. Among authors: song y. BMC Cancer. 2024 Jan 24;24(1):124. doi: 10.1186/s12885-024-11876-9. BMC Cancer. 2024. PMID: 38267866 Free PMC article. Clinical Trial.
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, Terui Y, Shin HJ, Kim WS, Cao J, Feng J, Eom HS, Kim TM, Tsai XC, Gau JP, Koh H, Zhang L, Song Y, Yang Y, Li W, Huang H, Ando K, Sharman JP, Sehn LH, Bu L, Wang X, Jiang Y, Hirata J, Lee C, Zhu J, Izutsu K. Song Y, et al. Blood. 2023 Apr 20;141(16):1971-1981. doi: 10.1182/blood.2022017734. Blood. 2023. PMID: 36626583 Free PMC article. Clinical Trial.
Safety of mesenchymal stem cells for clinical application.
Wang Y, Han ZB, Song YP, Han ZC. Wang Y, et al. Among authors: song yp. Stem Cells Int. 2012;2012:652034. doi: 10.1155/2012/652034. Epub 2012 May 16. Stem Cells Int. 2012. PMID: 22685475 Free PMC article.
Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.
Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, Huang H, Lai Y, Liu D, Liu Q, Luo Y, Jiang EL, Jiang M, Song Y, Tang XW, Wu D, Xia LH, Xu K, Zhang X, Zhang XH, Huang X. Wang Y, et al. Among authors: song y. Cancer Lett. 2024 Nov 28;605:217264. doi: 10.1016/j.canlet.2024.217264. Epub 2024 Sep 25. Cancer Lett. 2024. PMID: 39332587 Review.
Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group.
Xu LP, Lu DP, Wu DP, Jiang EL, Liu DH, Huang H, Sun ZM, Li NN, Liu QF, Zhang X, Lai YR, Song YP, Song XM, Liu SX, Zhang YC, Luo CJ, Xia LH, Niu T, Yu Y, Zhang XH, Tang XW, Luo Y, Huang XJ; Chinese Blood and Marrow Transplantation Registry Group. Xu LP, et al. Among authors: song yp, song xm. Transplant Cell Ther. 2023 Feb;29(2):136.e1-136.e7. doi: 10.1016/j.jtct.2022.11.011. Epub 2022 Nov 17. Transplant Cell Ther. 2023. PMID: 36402457 Free PMC article.
38,355 results
You have reached the last available page of results. Please see the User Guide for more information.